Teva's generic EpiPen approved in the U.S., with perfect timing - MarketWatch
Teva Pharmaceutical TEVA Pivots Trading Plans and Risk Controls - MarketWatch
Drug stocks move higher in late trading - MarketWatch
Teva Poised to Get a Big Boost in Generics - WSJ
Teva's stock has tumbled over 8 sessions and Morgan Stanley says it could fall 16% more - MarketWatch
Teva Pharmaceutical to pay $110 mln to settle opioid charges in W. Va. - MarketWatch
Israel stocks rise, led by Teva, ICL - MarketWatch
Teva's stock has tumbled over 8 sessions and Morgan Stanley says it could fall 16% more - MarketWatch
What To Do After TEVA Stock Falls Below $10 Again (NYSE:TEVA) | Seeking Alpha
Teva Pharmaceutical Settles Opioid Suit With West Virginia - MarketWatch
Teva beats first-quarter expectations but still has the same old problems - MarketWatch
Teva beats first-quarter expectations but still has the same old problems - MarketWatch
Israel stocks ease; Teva loses patent ruling - MarketWatch
Warren Buffett's firm trims stakes in drug makers, finance companies - MarketWatch
Scum of the earth': Opioid victims unload on Purdue Pharma owners - MarketWatch
Teva Pharmaceuticals - Wikipedia
Israel stocks lower; Ness agrees to takeover - MarketWatch
There's scant evidence so far for chloroquine as a COVID-19 drug — but there's already a shortage - MarketWatch
Israel stocks up; FTC eyes Teva-Cephalon deal - MarketWatch
Opinion: Multinationals learn the limits of being big - MarketWatch
Teva Pharmaceutical TEVA Pivots Trading Plans and Risk Controls - MarketWatch
Teva Pharmaceuticals stock falls 11% after earnings miss - MarketWatch
Teva stock drops 10% as generics turnaround looks uncertain - MarketWatch
Is the new Teva x Ugg collection fashion-forward or just plain ugly? - MarketWatch
